Overview

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Status:
Completed

Trial end date:
2020-01-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Lisdexamfetamine Dimesylate